Wolverine, GLOW and KLOW: what is actually in them, and what is actually known

What the marketing actually claims

Stated fairly, because the claims are specific rather than vague and that is part of why they land:

• Systemic healing — that BPC-157 accelerates repair of tendon, ligament, muscle and gut lining, and works wherever it is needed rather than only at the injection site.
• New blood supply — that both BPC-157 and TB-500 promote angiogenesis, which is a real bottleneck in tendon healing, since tendons are poorly vascularised and that is a genuine reason they heal slowly.
• Skin and collagen — GHK-Cu, which is where GLOW gets both its name and its appearance-focused pitch.
• Calmer inflammation — KPV, added in KLOW, usually pitched at gut inflammation and skin.
• Remarkable safety — "no reported side effects", which is a claim that sounds like a finding and is in fact a description of how little anyone has looked.

You will also see the framing that these are "what pro athletes use", the nickname "Wolverine" doing obvious work, and a lot of citations to studies — which, as below, are almost entirely rodent studies from one laboratory.

Why someone takes them separately

• One problem, one tool. Someone with a gut issue is interested in BPC-157 and has no reason to buy the copper peptide. Someone chasing skin wants GHK-Cu and nothing else.
• You can tell what did what. Change one thing and any effect — good, bad, or a reaction — has one candidate explanation. This is the single biggest practical argument, and it is the one most often given up first.
• Independent control. Different components have different intended timelines. Fixed in a blend, you cannot stop one, extend another, or change the ratio without discarding the vial.
• Cost. Buying one is cheaper than buying four, particularly if three of them are not aimed at your problem.

Why someone takes them stacked

• One injection instead of four. Not a small thing. Adherence to anything self-injected falls off sharply with the number of separate steps, and a single vial is the difference between doing it and not.
• The layered theory. The pitch is that each addresses a different layer of the same repair process — tissue, blood supply, collagen remodelling, inflammation — so the combination should do more than the parts. This is plausible reasoning. It is also entirely reasoning: see below.
• Simplicity and price. One purchase, one reconstitution, one number to remember, and a blend usually costs less than the four bought individually.

"It really chilled me out" — the effect people report that nobody advertises

This comes up constantly and almost never in the marketing, which sells tendons and skin. People on these — KLOW especially, but also plain BPC-157 — frequently report feeling calmer, less irritable, better able to sleep. It is worth taking seriously rather than waving away, and it is worth understanding why the usual explanation for it is wrong.

The gut-serotonin explanation is half right, in the half that does not matter

The version you will hear is: most of your serotonin is made in your gut, these peptides heal your gut, so they lift your mood. The first part is true — roughly 90–95% of the body's serotonin is made in the gut, by enterochromaffin cells, not in the brain.

The problem is the next step. Gut serotonin does not cross the blood-brain barrier. It is a functionally separate pool doing a different job — gut motility, digestive reflexes, the enteric nervous system. Your brain synthesises its own. So "most of your serotonin is in your gut" is a real fact that does not support the conclusion people hang on it, and any seller using it as the mechanism is repeating something they have not checked.

What could actually be going on

• BPC-157 acting on the brain directly — the strongest candidate. There is a genuine body of rodent work here: anxiolytic effects in elevated plus-maze testing, antidepressant-like effects in forced-swim and learned-helplessness models, and reported effects on dopamine and serotonin systems including raised hippocampal serotonin. Note the irony — the preclinical mood literature is arguably better developed than the tendon literature it is actually sold for. All rodent. No human trial for any psychiatric endpoint.
• The gut-brain axis, by the real routes. The connection is genuine, just not via serotonin travelling north — it runs through vagal signalling, immune and inflammatory pathways, and tryptophan availability. Gut inflammation demonstrably affects mood, so something that reduced it plausibly could too. Plausibly.
• Simply hurting less. Chronic pain is exhausting and corrosive to mood in a way people stop noticing until it lifts. If the shoulder is better, you are calmer, and no novel mechanism is required.
• Expectation. Calm and irritability are subjective, they fluctuate anyway, and they respond to believing you are doing something about your health. This is the hardest one to rule out and it is doing more work than most people credit.

One detail that argues against the tidiest theory: KPV — the anti-inflammatory component people usually point at — is in KLOW but not GLOW. If both produce the effect, KPV is not the explanation, and the common factor is BPC-157, which is in everything including the plain vials.

Nobody has tested any of this in people. What is fair to say: it is reported often enough to be worth noting, the mechanism usually given for it is wrong, at least one real mechanism exists that could account for it, and none of that has been demonstrated in a human. If it is the effect you are actually after, that is worth knowing about yourself — because it is not what you are being sold, and there are treatments for it with evidence behind them.

"But my naturopath prescribed it"

People genuinely are prescribed BPC-157 and TB-500 by Canadian practitioners. That is happening, and it does not mean the substances are approved — a prescription is a practitioner's decision, while approval is a finding that something was assessed. The route is compounding, which is regulated by provincial pharmacy colleges rather than by Health Canada, and it is a gap the colleges have started closing.

It is enough of a subject on its own that it has its own page: how unapproved drugs get prescribed in Canada — what the rules actually require, why the oral and injectable forms sit differently, and the two questions worth asking whoever is prescribing.

If you are tested in sport, stop here

BPC-157 and TB-500 are both on the WADA Prohibited List, banned at all times, in and out of competition. This applies at essentially every level that tests — including masters and amateur events far below the professional tier. A US regulatory change to compounding status would not alter this: WADA maintains its own list independently of the FDA.

And the tendon that started this

It would be a poor article that spent this long on why the appealing answer is unproven without coming back to the actual problem. The unglamorous option does have evidence behind it: progressive loading — heavy, slow, structured, continued for months rather than weeks — is the best-supported treatment for most chronic tendinopathy. It gets abandoned early because it is boring and because it is normal for it to hurt somewhat while it works. A physiotherapist who programmes it properly is a different experience from being told to do some stretches.

None of which proves the peptides do nothing. Absence of evidence is not evidence of absence, and what would settle it is ordinary: a published human trial, from a group independent of the original lab, showing an effect on something that matters. Until that exists, nobody knows — including the people selling it, and including anyone who tells you otherwise.

What is worth weighing in the meantime is the asymmetry. On one side, a treatment that is dull, slow, well evidenced and free. On the other, a vial whose entire human safety record is two people. Worth exhausting the first before paying for the second.